SHAREHOLDER INFORMATION MEDICLINIC ANNUAL REPORT 2017 231 SHAREHOLDER INFORMATION FINANCIAL CALENDAR Last date to trade cum dividend (SA register) Tuesday, 20 June 2017 First date of trading ex-dividend (SA register) Wednesday, 21 June 2017 First date of trading ex-dividend (UK register) Thursday, 22 June 2017 Record date for final dividend Friday, 23 June 2017 Shareholder approval at annual general meeting (London) Tuesday, 25 July 2017 Final dividend payment date Monday, 31 July 2017 Financial half year Saturday, 30 September 2017 Half year results announcement and presentation November 2017 DIVIDENDS AR The Company s dividend policy, details of the final dividend declared and the dividend access trust established for South African resident shareholders are provided in the Directors Report on page 18 and in note 13 of the consolidated financial statements on page 181. DISTRIBUTION OF ORDINARY SHAREHOLDERS AS AT 31 MARCH 2017 Number of beneficial shareholders Number of shares % of issued UK register 650 163 991 301 22.24 SA register 42 694 573 252 509 77.76 Certificated 1 093 406 318 0.06 Dematerialised 41 601 572 846 191 77.70 43 344 737 243 810 100.00 SHARE PRICE The latest share price information can be found on the Company s website at www.mediclinic.com or through your broker.
232 MEDICLINIC ANNUAL REPORT 2017 SHAREHOLDER INFORMATION SHAREHOLDER SERVICES AND CONTACTS SHAREHOLDER ENQUIRIES Enquiries relating to shareholdings, including notification of change of address, queries regarding the loss of a share certificate and dividend payments should be made to the Company s registrars: SHAREHOLDERS ON THE SOUTHERN AFRICAN REGISTER South African transfer secretary Namibian transfer secretary Computershare Investor Services (Pty) Ltd Transfer Secretaries (Pty) Ltd Rosebank Towers, 15 Biermann Avenue, 4 Robert Mugabe Avenue, Windhoek, Namibia Rosebank, 2196, South Africa Postal address: PO Box 2401, Windhoek, Namibia Postal address: PO Box 61051, Tel: +264 61 227 647 Marshalltown, 2107, South Africa Fax: +264 61 248 531 Tel: +27 11 370 5000 Fax: +27 11 688 7716 SHAREHOLDERS ON THE UK REGISTER With effect from Monday, 21 August 2017, the Company will change its UK registrar from Capita Asset Services to Computershare Investor Services plc. From this date, the administration of the Company s share register will cease to be provided by Capita and will instead be provided by Computershare. All shareholder services previously provided by Capita will be provided by Computershare and any questions relating to the Company s register should be directed to Computershare using the contact details below. Once the change of the share services is complete, Computershare will contact all shareholders on the UK register with more detail and information including their new Shareholder Reference Number ( SRN ) and how shareholders can register for online services to manage their shareholding. Capita Asset Services (up to Friday, 18 August 2017) The Registry, 34 Beckenham Road, Beckenham, Kent, BR3 4TU, United Kingdom Tel: 0871 664 0300 (UK only) or +44 371 664 0300 (if dialling from outside the UK) Lines are open during normal business hours from 08:30 to 17:30 GMT Monday to Friday, and calls are charged at the standard rate. Shareholders can use Capita s website to check and maintain their records. Details can be found at www.signalshares.com. Computershare (from Monday, 21 August 2017) The Pavilions, Bridgwater Road, Bristol, BS99 6ZZ, United Kingdom Tel: +44 370 703 6022 E-mail: WebCorres@computershare.co.uk Lines are open during normal business hours from 08:30 to 17:30 GMT Monday to Friday and charged at the standard rate. Shareholders can use Computershare s website to check and maintain their records. Details can be found at www.investorcentre.co.uk/contactus. Share Dealing Service Capita and Computershare offer a share dealing service which allows UK resident shareholders to buy and sell the Company s shares. Shareholders can deal in their shares on the internet or by telephone. Please contact the Company s registrar for more details on this service. ShareGift If a few shares are held, which low value makes them difficult to sell, you may make a donation to charity through ShareGift, an independent charity share donation scheme. For further details please contact the Company s registrar or ShareGift at telephone number +44 20 7930 3737 or visit their website at www.sharegift.org.
COMPANY INFORMATION MEDICLINIC ANNUAL REPORT 2017 233 COMPANY INFORMATION COMPANY NAME AND NUMBER Mediclinic International plc (formerly Al Noor Hospitals Group plc) (incorporated and registered in England and Wales) Company number: 08338604 REGISTERED OFFICE Mediclinic International plc, 40 Dukes Place, London, EC3A 7NH, United Kingdom Postal address: PO Box 456, Stellenbosch 7599, South Africa Tel: +44 20 7954 9600 Fax: +44 20 7954 9886 Ethics Line: +27 12 543 5332 / Toll-free 0800 005 316 (South Africa only) / ethics@mediclinic.com E-mail: info@mediclinic.com Website: www.mediclinic.com LISTING FTSE sector: Health Care Equipment & Services ISIN code: GB00B8HX8Z88 SEDOL Number: B8HX8Z8 EPIC Number: MDC LEI: 2138002S5BSBIZTD5I60 Primary listing: London Stock Exchange (share code: MDC) Secondary listing: JSE Limited (share code: MEI) Secondary listing: Namibian Stock Exchange (share code: MEP) DIRECTORS Dr Edwin Hertzog (Chairman) (South African), Danie Meintjes (Chief Executive Officer) (South African), Jurgens Myburgh (Chief Financial Officer) (South African), Jannie Durand (ne) (South African), Alan Grieve (ind ne) (British), Seamus Keating (ind ne) (Irish), Prof Dr Robert Leu (ind ne) (Swiss), Nandi Mandela (ind ne) (South African), Trevor Petersen (ind ne) (South African), Desmond Smith (Senior Independent Director) (South African), Pieter Uys (alternate to Jannie Durand) (South African) COMPANY SECRETARY REGISTRAR/TRANSFER SECRETARIES United Kingdom: Capita Asset Services (up to Friday, 18 August 2017) The Registry, 34 Beckenham Road, Beckenham, Kent, BR3 4TU Tel: 0871 664 0300 (UK only) or +44 371 664 0300 (if dialling from outside the UK) Computershare (from Monday, 21 August 2017) The Pavilions, Bridgwater Road, Bristol, BS99 6ZZ, United Kingdom Tel: +44 370 703 6022 E-mail: WebCorres@computershare.co.uk South Africa: Computershare Investor Services (Pty) Ltd Rosebank Towers, 15 Biermann Avenue, Rosebank, 2196, PO Box 61051, Marshalltown, 2107 Tel: +27 11 370 5000 Namibia: Transfer Secretaries (Pty) Ltd 4 Robert Mugabe Avenue, Windhoek, PO Box 2401, Windhoek Tel: +264 61 227 647 CORPORATE ADVISORS Auditors PricewaterhouseCoopers LLP, London Corporate Broker and Sponsors Corporate broker: Morgan Stanley & Co International plc JSE (South Africa) sponsor: Rand Merchant Bank (a division of FirstRand Bank Limited) NSX (Namibia) sponsor: Simonis Storm Securities (Pty) Ltd Legal Advisors UK legal advisors: Slaughter and May SA legal advisors: Cliffe Dekker Hofmeyr Inc. Remuneration Consultant New Bridge Street Communication Agency FTI Consulting Tel: +44 20 3727 1000 E-mail: businessinquiries@fticonsulting.com Capita Company Secretarial Services Limited (Ms Victoria Dalby) 40 Dukes Place, London, EC3A 7NH, United Kingdom Tel: +44 20 7954 9600 E-mail: MediclinicInternational@capita.co.uk INVESTOR RELATIONS CONTACT Mr James Arnold Head of Investor Relations 14 Curzon Street, London, W1J 5HN, United Kingdom Tel: +44 20 3786 8180/1 E-mail: ir@mediclinic.com
234 MEDICLINIC ANNUAL REPORT 2017 GLOSSARY GLOSSARY TERM annual general meeting Annual Report Al Noor Articles Board CAGR (%) cash conversion (%) CCU CDLI Combination Company Directors DRG EBITDA FCA GDP MEANING the annual general meeting of the Company to be held on Tuesday, 25 July 2016, the notice of which have been distributed to shareholder by Friday, 23 June 2017 and a copy of which is available on the Company s website this annual report and financial statements for the reporting period ended 31 March 2017 the Al Noor Hospitals Group with operations mainly in Abu Dhabi, which forms part of the Group s operations in the United Arab Emirates the Company s Articles of Association as adopted in General Meeting on 20 July 2016 the board of directors of Mediclinic International plc (formerly Al Noor Hospitals Group plc) compounded annual growth rate cash generated from operations divided by normalised EBITDA critical care unit Carbon Disclosure Leadership Index the combination of Al Noor Hospitals Group plc and Mediclinic International Limited, which was completed on 15 February 2016 Mediclinic International plc (formerly Al Noor Hospitals Group plc) the directors of Mediclinic International plc Diagnosis-related group operating profit before depreciation and amortisation, excluding other gains and losses the United Kingdom Financial Conduct Authority gross domestic product GRI Standards the GRI Sustainability Reporting Standards issued in 2016 by the Global Sustainability Standards Board, which standards represent global best practice for reporting publicly on a range of economic, environmental and social impacts Group group HAI Hirslanden Mediclinic International and its three operating platforms in Southern Africa, Switzerland and the United Arab Emirates ( group refers to one of the Group s operating platforms, as the context may indicate, as defined below) one of the operating platforms of the Group, as the context may indicate (please note that group is as defined in this definition and Group refers to the entire Mediclinic Group as defined above) healthcare-associated infection the Group s operations in Switzerland, trading under the Hirslanden brand, with Hirslanden AG as the intermediary holding company of the Group s operations in Switzerland
GLOSSARY MEDICLINIC ANNUAL REPORT 2017 235 TERM IFRS JCI JSE Last Practicable Date Listing Rules LSE Mediclinic or Mediclinic International Mediclinic Middle East Mediclinic Southern Africa next financial year NSX operating platform/s period under review reporting period SA SA Companies Act UAE UK UK Companies Act MEANING International Financial Reporting Standards, as adopted by the European Union Joint Commission International, an international quality measurement accreditation organisation, aimed at improving quality of care JSE Limited, the stock exchange of South Africa based in Johannesburg the date of approval of the Annual Report by the Board, being 23 May 2017 the listing rules of the FCA applicable to companies listed on the LSE, subject to the oversight of the United Kingdom Listing Authority the stock exchange operated by London Stock Exchange plc Mediclinic International plc (formerly Al Noor Hospitals Group plc) the Group s operations in the UAE, trading under the Mediclinic and Al Noor brands, with (a) Emirates Healthcare Holdings Limited BVI as the intermediary holding company of the Group s operations in the UAE, mainly in Dubai; and (b) Al Noor Golden Commercial LLC as the intermediary holding company of the Group s operations in the UAE, mainly in Abu Dhabi the Group s operations in South Africa and Namibia, trading under the Mediclinic brand, with Mediclinic Southern Africa (Pty) Ltd as the intermediary holding company of the Group s operations in South Africa and Namibia the financial year which commenced on 1 April 2017 and ending on 31 March 2018 the Namibian Stock Exchange based in Windhoek, Namibia Mediclinic Southern Africa, Hirslanden (Switzerland) and Mediclinic Middle East and their subsidiaries and associated entities, or any one of them as the context may indicate the financial year which commenced on 1 April 2016 and ended on 31 March 2017 the financial year which commenced on 1 April 2016 and ended on 31 March 2017 the Republic of South Africa the South African Companies Act, 71 of 2008, as amended United Arab Emirates the United Kingdom of Great Britain and Northern Ireland the United Kingdom Companies Act of 2006, as amended
236 MEDICLINIC ANNUAL REPORT 2017 FORWARD-LOOKING STATEMENTS FORWARD-LOOKING STATEMENTS This Annual Report contains certain forward-looking statements relating to the financial condition, regulatory environment in which we operate, results of operations and businesses of Mediclinic and the Group, including certain plans and objectives of the Group. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. Forward-looking statements are statements of future expectations that are based on management s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in these statements. Forward-looking statements include, among other things, statements concerning the potential exposure of Mediclinic to market risks and statements expressing management s expectations, beliefs, estimates, forecasts, projections and assumptions, including as to future potential cost savings, synergies, earnings, cash flow, production and prospects. These forward-looking statements are identified by their use of terms and phrases such as anticipate, believe, could, estimate, expect, goals, intend, may, objectives, outlook, plan, probably, project, risks, seek, should, target, will and similar terms and phrases.